Edgar Filing: ENANTA PHARMACEUTICALS INC - Form 4

ENANTA PHARMACEUTI Form 4 July 22, 2016	CALS INC					
FORM 4 LINITED				OMB A	PPROVAL	
UNITED	OMB Number:	3235-0287				
Check this box if no longer subject to Section 16. Form 4 or	OWNERSHIP OF	Expires: January 31 2005 Estimated average burden hours per response 0.5				
obligations	(a) of the Public U	16(a) of the Securities Exch Jtility Holding Company Ac nvestment Company Act of	et of 1935 or Section			
(Print or Type Responses)						
1. Name and Address of Reporting Luly Jay R.	Symbol	er Name and Ticker or Trading TA PHARMACEUTICALS ENTA]	5. Relationship of Issuer S (Checl	Reporting Per		
(Last) (First) (C/O ENANTA PHARMACEUTICALS, IN ARSENAL STREET	(Month/ 07/20/2	of Earliest Transaction Day/Year) 2016	X Director X Officer (give below) Presi		b Owner er (specify	
Filed(Month/Day/Year) Applical _X_For For			Applicable Line) _X_ Form filed by O Form filed by M	r Joint/Group Filing(Check) by One Reporting Person by More than One Reporting		
(City) (State)	(Zip)	la L. Non Donivative Committee	Person	on Donoficial	lly Owned	
1.Title of 2. Transaction Date Security (Month/Day/Year) (Instr. 3)	14	3. 4. Securities 3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Pric	5. Amount of 6. Securities Fe Beneficially (I Owned (I Following (I Reported Transaction(s) (Instr. 3 and 4)	Ownership orm: Direct D) or Indirect	7. Nature of Indirect	
Reminder: Report on a separate lin	e for each class of sec	urities beneficially owned directly	y or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. D S (I
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 14	07/20/2016		А	6,967	07/20/2016	03/20/2023	Common Stock	6,967	

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships				
1	Director	10% Owner	Officer	Other	
Luly Jay R. C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN, MA 02472	Х		President and CEO		
Signatures					
/s/ Nathaniel S. Gardiner as attorney-in-fact	07/22/2	2016			
<u>**</u> Signature of Reporting Person	Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On March 20, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, which does not become reportable on Form 4 until the option becomes exercisable. The option becomes exercisable in up to nine installments, six of which are

(1) installments of 8.33% of the shares and three of which are installments of 16.67% of the shares, based on ENTA's achievement of certain clinical milestones with respect to three or more programs that progress in clinical development. Two other installments of the option shares have previously become exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.